NKGen Biotech, Inc.

Graf Acquisition Corp. IV (Nasdaq: GFOR), a blank-check company sponsored by Graf Holdings and led by James Graf, filed an 8-K with the SEC on December 21, 2022, in connection with its proposed business combination with NKGen Biotech, Inc., a clinical-stage cell therapy company developing natural killer cell-based treatments targeting oncology and neurodegenerative diseases. The SPAC completed its IPO in 2021 and operates within the biotechnology sector. The filing reflects ongoing disclosure obligations as the parties advanced toward a definitive merger. Investors seeking complete filing histories, timeline data, and real-time SPAC analytics on GFOR and hundreds of other transactions can sign up for full data access at SpacDesk.